Bob Hugin’s Celgene background highlighted in campaign materials

Bob Hugin’s Celgene background highlighted in campaign materials The passage merely outlines Hugin’s career at Celgene and his political candidacy, with no specific allegations, financial transactions, or novel connections to misconduct. It provides background context but lacks actionable leads for investigation. Key insights: Bob Hugin was CEO and later executive chairman of Celgene before running for U.S. Senate in New Jersey.; Celgene’s flagship drug Revlimid generated $8.2 billion in 2017 sales.; Hugin’s campaign references his military service and leadership at Celgene.